| Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review L Peyrin-Biroulet, N Williet, P Cacoub The American journal of clinical nutrition 102 (6), 1585-1594, 2015 | 429 | 2015 |
| Dietary beliefs and behavior among inflammatory bowel disease patients C Zallot, D Quilliot, JB Chevaux, C Peyrin‐Biroulet, ... Inflammatory bowel diseases, 2012 | 281 | 2012 |
| Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease L Peyrin-Biroulet, A Oussalah, N Williet, C Pillot, L Bresler, MA Bigard Gut 60 (7), 930-936, 2011 | 268 | 2011 |
| Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease N Williet, WJ Sandborn, L Peyrin–Biroulet Clinical Gastroenterology and Hepatology 12 (8), 1246-1256. e6, 2014 | 257 | 2014 |
| Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC) C Neuzillet, S Gaujoux, N Williet, JB Bachet, L Bauguion, LC Durand, ... Digestive and Liver Disease 50 (12), 1257-1271, 2018 | 170 | 2018 |
| Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide … A Lievre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... European Journal of Cancer 141, 62-81, 2020 | 149 | 2020 |
| Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial X Roblin, G Boschetti, N Williet, S Nancey, H Marotte, A Berger, JM Phelip, ... Alimentary pharmacology & therapeutics 46 (2), 142-149, 2017 | 145 | 2017 |
| Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients N Williet, H Sarter, C Gower-Rousseau, C Adrianjafy, A Olympie, ... Journal of Crohn's and Colitis 11 (2), 165-174, 2017 | 144 | 2017 |
| Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months N Williet, G Boschetti, M Fovet, T Di Bernado, P Claudez, E Del Tedesco, ... Clinical Gastroenterology and Hepatology 15 (11), 1750-1757. e3, 2017 | 141 | 2017 |
| Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab B Ungar, U Kopylov, T Engel, M Yavzori, E Fudim, O Picard, A Lang, ... Alimentary pharmacology & therapeutics 45 (2), 276-282, 2017 | 140 | 2017 |
| Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study A Zaanan, N Williet, M Hebbar, TS Dabakuyo, L Fartoux, T Mansourbakht, ... Journal of hepatology 58 (1), 81-88, 2013 | 138 | 2013 |
| Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective … X Roblin, N Williet, G Boschetti, JM Phelip, E Del Tedesco, AE Berger, ... Gut 69 (7), 1206-1212, 2020 | 129 | 2020 |
| Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study W Yacoub, N Williet, L Pouillon, T Di‐Bernado, M De Carvalho Bittencourt, ... Alimentary pharmacology & therapeutics 47 (7), 906-912, 2018 | 108 | 2018 |
| Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials N Williet, Q Tournier, C Vernet, O Dumas, L Rinaldi, X Roblin, JM Phelip, ... Endoscopy 50 (09), 846-860, 2018 | 78 | 2018 |
| FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI. 3 for first-line treatment of metastatic pancreatic … L Dahan, JM Phelip, K Le Malicot, N Williet, J Desrame, J Volet, C Petorin, ... Journal of Clinical Oncology 36 (15_suppl), 4000-4000, 2018 | 77 | 2018 |
| Reliability and accuracy of a novel classification system using peroral cholangioscopy for the diagnosis of bile duct lesions C Robles-Medranda, M Valero, M Soria-Alcivar, M Puga-Tejada, R Oleas, ... Endoscopy 50 (11), 1059-1070, 2018 | 71 | 2018 |
| Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics N Williet, C Pillot, A Oussalah, V Billioud, JB Chevaux, L Bresler, ... Inflammatory bowel diseases 18 (9), 1641-1646, 2012 | 71 | 2012 |
| Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial L Dahan, N Williet, K Le Malicot, JM Phelip, J Desrame, O Bouché, ... Journal of Clinical Oncology 39 (29), 3242-3250, 2021 | 57 | 2021 |
| Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study N Williet, A Saint, AL Pointet, D Tougeron, S Pernot, A Pozet, D Bechade, ... Therapeutic advances in gastroenterology 12, 1756284819878660, 2019 | 51 | 2019 |
| Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn’s disease N Soufflet, G Boschetti, X Roblin, C Cuercq, N Williet, AL Charlois, ... Clinical Gastroenterology and Hepatology 17 (12), 2610-2612, 2019 | 48 | 2019 |
